Share

IN THIS ISSUE

The World Health Organization has come under fire for its handling of the Covid-19 pandemic, with critics such as US President Donald Trump quick to claim that the organisation had failed to react fast enough to prevent the virus from spreading. We look back at the history of the organisation to find out how its reaction to Covid-19 compares to previous health emergencies.


Also, we find out more about the RECOVERY trial - a colossal undertaking in the UK that aims to assess the anti-coronavirus efficacy of a number of existing treatments, examine what is needed to salvage the clinical trials disrupted by Covid-19, and, as treatment options beginning to emerge for this novel coronavirus, we investigate what this unique situation means for intellectual property as governments waive common patent protections in pursuit of a cure.


Plus, we examine whether drug manufacturers can keep up with the evolution of seasonal allergies, round up key developments in biologic drugs, explore the difficulties of breaking through the blood brain barrier, and review the highs and lows of immunotherapy.

Go to article: Home | Breaking the BarrierGo to article: In this issueGo to article: NSFGo to article: ContentsGo to article: AlmacGo to article: NewsGo to article: VEGA Company Insight Go to article: VEGA AustraliaGo to article: Covid-19 executive briefing by GlobalDataGo to article: Gilead’s remdesivir a candidate for US government stockpiling or bulk buying in Go to article: Covid-19’s impact on trial PROs, other endpoints can be addressed via data stratification, sensitivity analysisGo to article: ILC Dover Go to article: Vitamin D affects Covid-19 mortalityGo to article: Clinical trial disruption due to Covid-19 has begun to slowGo to article: Covid-19 boosts big bio/pharma drug sales but Regeneron may be falling shortGo to article: MimotopesGo to article: The pharma industry briefingGo to article: Charting the ups and downs of the World Health OrganizationGo to article: Road to RECOVERY: a deep dive into the world’s largest Covid-19 drug trialGo to article: Salvaging clinical trials in the time of Covid-19Go to article: Intellectual property in the time of Covid-19Go to article: Molnár-Institute Company InsightGo to article: Molnar-InstituteGo to article: A plight for sore eyes: the latest developments in seasonal allergy treatmentGo to article: How research groups are tackling the problem of biologic drug delivery Go to article: Breaking the blood-brain barrier: neurology’s greatest challengeGo to article: Timeline: charting the history of immunotherapy, cancer treatment's fourth pillarGo to article: Creating a sure data footing for AIGo to article: Koehler eClinicalGo to article: Deals in brief powered by GlobalDataGo to article: The key list powered by GlobalDataGo to article: Global markets and indices powered by GlobalDataGo to article: Macro-economic indicators (1 of 2) powered by GlobalDataGo to article: Macro-economic indicators (2 of 2) powered by GlobalDataGo to article: EventsGo to article: Next issue